Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | HRH1 | P35367 | 1/20 | 0.68 |
| ▸ | HTR2B | P41595 | 1/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.68 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7818974 | 0.99 | TACR1 (0.76) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6554450 | 0.90 | TACR1 (0.74) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6556858 | 0.89 | TACR1 (0.76) | TACR1CYP2D6 | |
| Hydrochloric Acid SCHEMBL7475900 | 0.89 | TACR1 (0.73) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6555202 | 0.88 | TACR1 (0.74) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL7474243 | 0.88 | TACR1 (0.74) | TACR1CYP2D6HTR1AHTR2AHTR2C | |
| SCHEMBL6554698 | 0.87 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6554707 | 0.87 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL8872819 | 0.87 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6555223 | 0.87 | TACR1 (0.80) | TACR1CYP2D6KCNH2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1411946-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS TO MODIFY UNWANTED BEHAVIOR IN DOGS, CATS AND HORSES | Pfizer Products Inc. (US) | 2004-04-28 | — | — | EP | claimed |
| EP-0721778-B1 | NK-1 receptor antagonists for the treatment of neuronal injury and stroke | PFIZER (US) | 2004-03-03 | — | — | EP | claimed |
| JP-2003523941-A | — | — | 2003-08-12 | — | — | JP | claimed |
| US-20030139443-A1 | Use of tachykinin antagonists, including NK-1 receptor antagonists, to modify unwanted behavior in dogs, cats and horses | BRONK BRIAN SCOTT (US) | 2003-07-24 | — | — | US | claimed |
| WO-2003009848-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS TO MODIFY UNWANTED BEHAVIOR IN DOGS, CATS AND HORSES | PFIZER PRODUCTS INC. (US) | 2003-02-06 | — | — | WO | claimed |
| EP-1209157-A1 | Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds | PFIZER INC. (US) | 2002-05-29 | — | — | EP | claimed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| EP-0790825-A1 | NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EYE DISORDERS | PFIZER INC. (US) | 1997-08-27 | — | — | EP | claimed |
| US-5576317-A | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis | PFIZER INC. (US) | 1996-11-19 | — | — | US | claimed |
| EP-0721778-A2 | NK-1 receptor antagonists for the treatment of neuronal injury and stroke | PFIZER INC. (US) | 1996-07-17 | — | — | EP | claimed |
| EP-0715855-A2 | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis | PFIZER INC. (US) | 1996-06-12 | — | — | EP | claimed |
| WO-1996014845-A1 | NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EYE DISORDERS | PFIZER INC. (US) | 1996-05-23 | — | — | WO | claimed |
| EP-0655246-A1 | Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria | PFIZER INC. (US) | 1995-05-31 | — | — | EP | claimed |
| EP-0653208-A2 | Pharmaceutical agents for treatment or prevention of sunburn | PFIZER INC. (US) | 1995-05-17 | — | — | EP | claimed |
| WO-1995007908-A1 | HETEROARYLAMINO AND HETEROARYLSULFONAMIDO SUBSTITUTED 3-BENZYLAMINOMETHYL PIPERIDINES AND RELATED COMPOUNDS | PFIZER INC. (US) | 1995-03-23 | — | — | WO | claimed |
| EP-1411946-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS TO MODIFY UNWANTED BEHAVIOR IN DOGS, CATS AND HORSES | Pfizer Products Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| EP-0721778-B1 | NK-1 receptor antagonists for the treatment of neuronal injury and stroke | PFIZER (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-0653208-A2 | Pharmaceutical agents for treatment or prevention of sunburn | PFIZER INC. (US) | 1995-05-17 | — | — | EP | disclosed |
| WO-1995007908-A1 | HETEROARYLAMINO AND HETEROARYLSULFONAMIDO SUBSTITUTED 3-BENZYLAMINOMETHYL PIPERIDINES AND RELATED COMPOUNDS | PFIZER INC. (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139443-A1 | Use of tachykinin antagonists, including NK-1 receptor antagonists, to modify unwanted behavior in dogs, cats and horses | NPSR1, NTSR1, TACR1 | TACR1 3/4885CYP2D6 3618/4885KCNH2 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.